Stockscreener 앱 받기
1.30
7.14%
-0.10
시간 외 거래:
1.30
전일 마감가:
$1.40
열려 있는:
$1.4
하루 거래량:
127.23K
Relative Volume:
0.97
시가총액:
$18.58M
수익:
$48,200
순이익/손실:
$-16.66M
주가수익비율:
-0.7291
EPS:
-1.783
순현금흐름:
$-17.15M
1주 성능:
-12.16%
1개월 성능:
-22.16%
6개월 성능:
-38.68%
1년 성능:
-56.08%
1일 변동 폭
$1.27
$1.41
1주일 범위
$1.27
$1.51
52주 변동 폭
$1.27
$9.19
Dare Bioscience Inc Stock (DARE) Company Profile
명칭
Dare Bioscience Inc
전화
858-926-7655
주소
3655 NOBEL DRIVE, SAN DIEGO, CA
Compare DARE vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DARE
Dare Bioscience Inc
|
1.30 | 20.00M | 48,200 | -16.66M | -17.15M | -1.783 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Dare Bioscience Inc 주식(DARE)의 최신 뉴스
DARE BIOSCIENCE, INC. Files Form 8-K with SEC Reporting Unregistered Sale of Equity Securities - Minichart
Dare Bioscience secures NIH funding extension for preterm birth therapy - MSN
Dare Bioscience completes closing of Regulation A equity offering - Investing.com
Daré Bioscience (DARE) issues 43,050 preferred-and-warrant units - Stock Titan
DARE Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Dare Bioscience (DARE) Advances Investigational Preterm Birth Tr - GuruFocus
Daré Bioscience Receives NIH Funding Award Notice to - GlobeNewswire
Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-PTB1, its Novel Intravaginal Ring for Prevention of Preterm Birth - Sahm
Daré Bioscience Participates in Virtual Investor “What This Means” Segment - Sahm
Dare Bioscience Participates in Virtual Investor "What This Means" Segment - Bitget
Persistent HPV has no FDA-approved drug; Daré CEO lays out DARE-HPV trial plan - Stock Titan
Daré Bioscience Completes Second Closing of Regulation A Offering - TipRanks
Daré Bioscience (NASDAQ: DARE) advances Regulation A unit offering - Stock Titan
Daré Bioscience Updates Investor Presentation Under Regulation FD - TipRanks
Daré Bioscience (NASDAQ: DARE) updates investor presentation and furnishes 8-K - Stock Titan
DARE Should I Buy - Intellectia AI
DARE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Daré Bioscience gets FDA clearance for HPV treatment trial By Investing.com - Investing.com India
Daré Bioscience gets FDA clearance for HPV treatment trial - Investing.com Australia
Dare Bioscience Announces FDA Clearance of IND for Phase 2 Clinical Study of DARE-HPV, a Potential Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer - Bitget
Daré Bioscience Announces FDA Clearance of IND for Phase 2 - GlobeNewswire
Daré Bioscience Announces FDA Clearance of IND for Phase 2 Clinical Study of DARE-HPV, a Potential Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer - The Manila Times
Dare Bioscience (DARE) CEO subscribes to Reg A units with warrants - Stock Titan
DARE SEC FilingsDare Bioscience Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Dare Bioscience Launches Telehealth Consultations for Women's Arousal Cream - Intellectia AI
Dare Bioscience (DARE) Launches Telehealth for Topical Sildenafi - GuruFocus
First-of-its-kind arousal cream for women offers US-wide telehealth access - Stock Titan
Dare Bioscience Secures Strategic Autonomy with Key Asset Reversion - AD HOC NEWS
Daré Bioscience, Inc. (NASDAQ:DARE): Are Analysts Optimistic? - simplywall.st
Dare Bioscience launches preferred stock and warrant offering on Nasdaq - Investing.com
Daré Bioscience Launches Regulation A Preferred Unit Offering - TipRanks
Companies Like Daré Bioscience (NASDAQ:DARE) Are In A Position To Invest In Growth - Yahoo Finance
Dare Bioscience (NASDAQ:DARE) Share Price Passes Below 50-Day Moving Average – What’s Next? - Defense World
Daré Bioscience issues updated investor corporate presentation - MSN
Daré Bioscience Issues Updated Investor Corporate Presentation - TipRanks
Daré Bioscience, Inc. (NASDAQ:DARE) Q2 2025 Earnings Call Transcript - MSN
Daré targets DARE to PLAY launch in December 2025 as dual path strategy accelerates - MSN
Dare Bioscience secures additional NIAID funding for HPV treatment - MSN
Dare Bioscience Earnings Notes - Trefis
Is Dare Bioscience Inc (DARE) a opportunity to investors? - uspostnews.com
Viagra for women rolling out in select states - NewsNation
A History of Outperforming Analyst Forecasts and Beating the Odds: Dare Bioscience Inc (DARE) - setenews.com
‘Viagra’ for women hits the shelves – 30 years after men got little blue pills - AOL.com
Sildenafil cream for female sexual arousal disorder available to prescribe in select states - Urology Times
DARE to PLAY sildenafil cream becomes commercially available for women in select states - Contemporary OB/GYN
Dare Bioscience (DARE) Launches Prescription for Women's Topical Arousal Cream - GuruFocus
Daré Bioscience Launches First-Ever Sildenafil Cream for Women, DARE to PLAY™ Sildenafil Cream, Enhancing Female Arousal and Sexual Health - Quiver Quantitative
Daré Bioscience (NASDAQ: DARE) starts 503B DARE to PLAY cream access in select states - Stock Titan
Dare Bioscience stock maintains Buy rating at H.C. Wainwright as Bayer exits - Investing.com Canada
DARE: HC Wainwright & Co. Reiterates 'Buy' Rating with $12 Targe - GuruFocus
Daré Bioscience to regain rights to hormone-free contraceptive from Bayer By Investing.com - Investing.com Canada
Dare Bioscience Inc (DARE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):